Literature DB >> 30921477

Lifestyle changes in women with polycystic ovary syndrome.

Siew S Lim1, Samantha K Hutchison, Emer Van Ryswyk, Robert J Norman, Helena J Teede, Lisa J Moran.   

Abstract

BACKGROUND: Polycystic ovary syndrome (PCOS) affects 8% to 13% of reproductive-aged women and is associated with reproductive and metabolic dysfunction. Obesity worsens the presentation of PCOS and weight management (weight loss, maintenance or prevention of excess weight gain) is proposed as an initial treatment strategy, best achieved through lifestyle changes incorporating diet, exercise and behavioural interventions.
OBJECTIVES: To assess the effectiveness of lifestyle treatment in improving reproductive, anthropometric (weight and body composition), metabolic and quality of life factors in PCOS. SEARCH
METHODS: We searched the Cochrane Gynaecology and Fertility Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, PsycINFO, CINAHL and AMED (date of last search March 2018). We also searched controlled trials registries, conference abstracts, relevant journals, reference lists of relevant papers and reviews, and grey literature databases, with no language restrictions applied. SELECTION CRITERIA: Randomised controlled trials (RCTs) comparing lifestyle treatment (diet, exercise, behavioural or combined treatments) to minimal or no treatment in women with PCOS. DATA COLLECTION AND ANALYSIS: Two authors independently selected trials, assessed evidence quality and risk of bias, and extracted data. Our primary outcomes were live birth, miscarriage and pregnancy. We used inverse variance and fixed-effect models in the meta-analyses. We reported dichotomous outcomes as an odds ratio and continuous outcomes as a mean difference (MD) or standardised mean difference (SMD). MAIN
RESULTS: We included 15 studies with 498 participants. Ten studies compared physical activity to minimal dietary and behavioural intervention or no intervention. Five studies compared combined dietary, exercise and behavioural intervention to minimal intervention. One study compared behavioural intervention to minimal intervention. Risk of bias varied: eight studies had adequate sequence generation, seven had adequate clinician or outcome assessor blinding, seven had adequate allocation concealment, six had complete outcome data and six were free of selective reporting. No studies assessed the fertility primary outcomes of live birth or miscarriage. No studies reported the secondary reproductive outcome of menstrual regularity, as defined in this review.Lifestyle intervention may improve a secondary (endocrine) reproductive outcome, the free androgen index (FAI) (MD -1.11, 95% confidence interval (CI) -1.96 to -0.26, 6 RCTs, N = 204, I2 = 71%, low-quality evidence). Lifestyle intervention may reduce weight (kg) (MD -1.68 kg, 95% CI -2.66 to -0.70, 9 RCTs, N = 353, I2 = 47%, low-quality evidence). Lifestyle intervention may reduce body mass index (BMI) (kg/m2) (-0.34 kg/m2, 95% CI -0.68 to -0.01, 12 RCTs, N = 434, I2= 0%, low-quality evidence). We are uncertain of the effect of lifestyle intervention on glucose tolerance (glucose outcomes in oral glucose tolerance test) (mmol/L/minute) (SMD -0.02, 95% CI -0.38 to 0.33, 3 RCTs, N = 121, I2 = 0%, low-quality evidence). AUTHORS'
CONCLUSIONS: Lifestyle intervention may improve the free androgen index (FAI), weight and BMI in women with PCOS. We are uncertain of the effect of lifestyle intervention on glucose tolerance. There were no studies that looked at the effect of lifestyle intervention on live birth, miscarriage or menstrual regularity. Most studies in this review were of low quality mainly due to high or unclear risk of bias across most domains and high heterogeneity for the FAI outcome.

Entities:  

Mesh:

Year:  2019        PMID: 30921477      PMCID: PMC6438659          DOI: 10.1002/14651858.CD007506.pub4

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  115 in total

Review 1.  Cardiovascular risk management after reproductive and pregnancy-related disorders: A Dutch multidisciplinary evidence-based guideline.

Authors:  Karst Y Heida; Michiel L Bots; Christianne Jm de Groot; Frederique M van Dunné; Nurah M Hammoud; Annemiek Hoek; Joop Se Laven; Angela Hem Maas; Jeanine E Roeters van Lennep; Birgitta K Velthuis; Arie Franx
Journal:  Eur J Prev Cardiol       Date:  2016-07-18       Impact factor: 7.804

Review 2.  Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.

Authors:  Lara C Morley; Thomas Tang; Ephia Yasmin; Robert J Norman; Adam H Balen
Journal:  Cochrane Database Syst Rev       Date:  2017-11-29

3.  Effects of resistance training and endurance training on insulin sensitivity in nonobese, young women: a controlled randomized trial.

Authors:  E T Poehlman; R V Dvorak; W F DeNino; M Brochu; P A Ades
Journal:  J Clin Endocrinol Metab       Date:  2000-07       Impact factor: 5.958

4.  Effect of high-protein or normal-protein diet on weight loss, body composition, hormone, and metabolic profile in southern Brazilian women with polycystic ovary syndrome: a randomized study.

Authors:  Mariana K Toscani; Fernanda M Mario; Simone Radavelli-Bagatini; Denusa Wiltgen; Maria Cristina Matos; Poli Maria Spritzer
Journal:  Gynecol Endocrinol       Date:  2011-05-31       Impact factor: 2.260

Review 5.  Lifestyle modification programs in polycystic ovary syndrome: systematic review and meta-analysis.

Authors:  Juan Pablo Domecq; Gabriela Prutsky; Rebecca J Mullan; Ahmad Hazem; Vishnu Sundaresh; Mohammed B Elamin; Olivia J Phung; Amy Wang; Kathleen Hoeger; Renato Pasquali; Patricia Erwin; Amy Bodde; Victor M Montori; M Hassan Murad
Journal:  J Clin Endocrinol Metab       Date:  2013-10-03       Impact factor: 5.958

6.  Differences in dyslipidemia between American and Italian women with polycystic ovary syndrome.

Authors:  P A Essah; J E Nestler; E Carmina
Journal:  J Endocrinol Invest       Date:  2008-01       Impact factor: 4.256

7.  Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women.

Authors:  D S Guzick; R Wing; D Smith; S L Berga; S J Winters
Journal:  Fertil Steril       Date:  1994-04       Impact factor: 7.329

8.  Impact of a mindfulness stress management program on stress, anxiety, depression and quality of life in women with polycystic ovary syndrome: a randomized controlled trial.

Authors:  Charikleia Stefanaki; Flora Bacopoulou; Sarantis Livadas; Anna Kandaraki; Athanasios Karachalios; George P Chrousos; Evanthia Diamanti-Kandarakis
Journal:  Stress       Date:  2014-12-29       Impact factor: 3.493

9.  Randomized Controlled Trial of Preconception Interventions in Infertile Women With Polycystic Ovary Syndrome.

Authors:  Richard S Legro; William C Dodson; Penny M Kris-Etherton; Allen R Kunselman; Christy M Stetter; Nancy I Williams; Carol L Gnatuk; Stephanie J Estes; Jennifer Fleming; Kelly C Allison; David B Sarwer; Christos Coutifaris; Anuja Dokras
Journal:  J Clin Endocrinol Metab       Date:  2015-09-24       Impact factor: 5.958

Review 10.  Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome.

Authors:  Helena J Teede; Marie L Misso; Michael F Costello; Anuja Dokras; Joop Laven; Lisa Moran; Terhi Piltonen; Robert J Norman
Journal:  Fertil Steril       Date:  2018-07-19       Impact factor: 7.329

View more
  42 in total

Review 1.  Animal Models to Understand the Etiology and Pathophysiology of Polycystic Ovary Syndrome.

Authors:  Elisabet Stener-Victorin; Vasantha Padmanabhan; Kirsty A Walters; Rebecca E Campbell; Anna Benrick; Paolo Giacobini; Daniel A Dumesic; David H Abbott
Journal:  Endocr Rev       Date:  2020-07-01       Impact factor: 19.871

Review 2.  Prospective Risk of Type 2 Diabetes in Normal Weight Women with Polycystic Ovary Syndrome.

Authors:  Dorte Glintborg; Naja Due Kolster; Pernille Ravn; Marianne Skovsager Andersen
Journal:  Biomedicines       Date:  2022-06-20

3.  Tai Chi for Overweight/Obese Adolescents and Young Women with Polycystic Ovary Syndrome: A Randomized Controlled Pilot Trial.

Authors:  Yan Li; Changle Peng; Meiwei Zhang; Liangzhen Xie; Jinjin Gao; Yingji Wang; Yuanhe Gao; Lihui Hou
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-17       Impact factor: 2.650

4.  The Lifestyle Modifications and Endometrial Proteome Changes of Women With Polycystic Ovary Syndrome and Obesity.

Authors:  D Abdulkhalikova; A Sustarsic; Eda Vrtačnik Bokal; N Jancar; M Jensterle; T Burnik Papler
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-22       Impact factor: 6.055

Review 5.  Nutritional Supplements and Complementary Therapies in Polycystic Ovary Syndrome.

Authors:  Simon Alesi; Carolyn Ee; Lisa J Moran; Vibhuti Rao; Aya Mousa
Journal:  Adv Nutr       Date:  2022-08-01       Impact factor: 11.567

6.  Chinese herbal medicine for subfertile women with polycystic ovarian syndrome.

Authors:  Kunyan Zhou; Jing Zhang; Liangzhi Xu; Chi Eung Danforn Lim
Journal:  Cochrane Database Syst Rev       Date:  2021-06-04

7.  Pharmacological and non-pharmacological strategies for obese women with subfertility.

Authors:  Seyed Abdolvahab Taghavi; Madelon van Wely; Shayesteh Jahanfar; Fatemeh Bazarganipour
Journal:  Cochrane Database Syst Rev       Date:  2021-03-25

8.  The relationship between polycystic ovary syndrome and infertility: a bibliometric analysis.

Authors:  Sulian Zhuang; Chunxia Jing; Lei Yu; Liwei Ji; Weiwei Liu; Xingpo Hu
Journal:  Ann Transl Med       Date:  2022-03

Review 9.  Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists.

Authors:  Hellas Cena; Luca Chiovato; Rossella E Nappi
Journal:  J Clin Endocrinol Metab       Date:  2020-08-01       Impact factor: 5.958

10.  The therapeutic effects of glucagon-like peptide-1 receptor agonists and metformin on polycystic ovary syndrome: A protocol for systematic review and meta-analysis.

Authors:  Ruilin Ma; Xuesong Ding; Yanfang Wang; Yan Deng; Aijun Sun
Journal:  Medicine (Baltimore)       Date:  2021-06-11       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.